search
Back to results

Ultra-low-dose CACS in a Large Population (ULDCACSLARGE)

Primary Purpose

Coronary Artery Disease

Status
Terminated
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Ultra low-dose CTAC
Sponsored by
University of Zurich
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Coronary Artery Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients referred for a non-contrast enhanced CT scan for CAC scoring
  • Male and Female subjects ≥18 years of age,
  • Written informed consent

Exclusion Criteria:

  • Pregnancy or breast-feeding
  • CACS of 0 after inclusion of 50 patients with CACS 0 (as assessed visually after the first CT scan, prior to performing the 3 additional study scans)
  • History of coronary artery stenting, coronary artery bypass grafting, of implantation of cardiac devices (e.g. valve prosthesis, pacemaker, implantable cardioverter defibrillator etc.)
  • Enrolment of the investigator, his/her family members, employees and other dependent persons

Sites / Locations

  • Department of Nuclear Medicine, University Hospital Zurich

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Standard and ultra-low-dose CAC scoring

Arm Description

Outcomes

Primary Outcome Measures

Impact of BMI on CAC scores derived from low-dose versus standard-dose CT
Assessment of deviation of CAC scores derived from low-dose CT versus standard-dose CT (i.e. standard of reference) by calculating bias and Bland-Altmann limits of agreement as well as intraclass correlation in different subgroups of patients, stratified by body mass index.

Secondary Outcome Measures

Prognostic value of CAC scores derived from CT scans with varying tube voltages
Assessment of sensitivity and specificity CAC scores derived from low-dose CT versus standard-dose CT (i.e. standard of reference) to predict future cardiovascular events (i.e. myocardial infarction, revascularisation, death) over a short to mid-term follow-up period (i.e. 2 years).

Full Information

First Posted
July 26, 2018
Last Updated
November 7, 2022
Sponsor
University of Zurich
search

1. Study Identification

Unique Protocol Identification Number
NCT03637231
Brief Title
Ultra-low-dose CACS in a Large Population
Acronym
ULDCACSLARGE
Official Title
Ultra-low-dose Coronary Artery Calcium Scoring: Evaluation of Prognostic Performance and Impact of Physiological Factors on Quantification in a Large Population
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Terminated
Why Stopped
The preliminary findings render it very unlikely that the methodology can be refined further in order to yield more accurate results even if more patients would be included and the study would be continued.
Study Start Date
July 5, 2018 (Actual)
Primary Completion Date
October 25, 2021 (Actual)
Study Completion Date
October 25, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Radiation exposure to patients from CT for CAC scoring has steadily decreased in recent years. This is mainly achieved through lowering tube currents alongside with the introduction of iterative reconstruction algorithms which allow compensating for increased image noise. However, the greatest radiation dose reduction can be obtained by reducing peak tube voltage. Yet lowering peak tube voltage remains challenging because tissue attenuation is closely related to photon energy, thus rendering the established thresholds for calculating CAC scores (i.e. Agatston scores) incomparable if peak tube voltages other than the standard 120 kilovolt peak (kVp) are applied. The investigators have developed novel tube-adapted thresholds for CAC scoring by CT at 80 kVp and 70-kVp tube voltage and have shown that these novel thresholds are valid, yielding results closely comparable to the standard 120-kVp protocol. The present study aims to optimize application of such low-dose scans in a general population through assessment of the impact of physiological patient parameters on image parameters such as image noise which per se may impact the accuracy and feasibility of ultra-low-dose CAC scoring with reduced tube voltage. Furthermore, the prognostic performance of such low-dose CAC scoring will be elucidated.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
301 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard and ultra-low-dose CAC scoring
Arm Type
Other
Intervention Type
Diagnostic Test
Intervention Name(s)
Ultra low-dose CTAC
Intervention Description
All patients undergo two non-contrast enhanced CT scans with standard dose (i.e. 120 kVp), one with 80 kVp and one with 70 kVp.
Primary Outcome Measure Information:
Title
Impact of BMI on CAC scores derived from low-dose versus standard-dose CT
Description
Assessment of deviation of CAC scores derived from low-dose CT versus standard-dose CT (i.e. standard of reference) by calculating bias and Bland-Altmann limits of agreement as well as intraclass correlation in different subgroups of patients, stratified by body mass index.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Prognostic value of CAC scores derived from CT scans with varying tube voltages
Description
Assessment of sensitivity and specificity CAC scores derived from low-dose CT versus standard-dose CT (i.e. standard of reference) to predict future cardiovascular events (i.e. myocardial infarction, revascularisation, death) over a short to mid-term follow-up period (i.e. 2 years).
Time Frame
2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients referred for a non-contrast enhanced CT scan for CAC scoring Male and Female subjects ≥18 years of age, Written informed consent Exclusion Criteria: Pregnancy or breast-feeding CACS of 0 after inclusion of 50 patients with CACS 0 (as assessed visually after the first CT scan, prior to performing the 3 additional study scans) History of coronary artery stenting, coronary artery bypass grafting, of implantation of cardiac devices (e.g. valve prosthesis, pacemaker, implantable cardioverter defibrillator etc.) Enrolment of the investigator, his/her family members, employees and other dependent persons
Facility Information:
Facility Name
Department of Nuclear Medicine, University Hospital Zurich
City
Zurich
ZIP/Postal Code
8091
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29432592
Citation
Grani C, Vontobel J, Benz DC, Bacanovic S, Giannopoulos AA, Messerli M, Grossmann M, Gebhard C, Pazhenkottil AP, Gaemperli O, Kaufmann PA, Buechel RR. Ultra-low-dose coronary artery calcium scoring using novel scoring thresholds for low tube voltage protocols-a pilot study. Eur Heart J Cardiovasc Imaging. 2018 Dec 1;19(12):1362-1371. doi: 10.1093/ehjci/jey019.
Results Reference
background

Learn more about this trial

Ultra-low-dose CACS in a Large Population

We'll reach out to this number within 24 hrs